down arrow

Viracta Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US92765F1084
USD
0.01
0 (2.08%)

Jul 16

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.010.01

52 Week

0.010.30
Valuation
Technical
Day's Volume

CASH

484.03 k

Shareholding (Sep 2024)

FII

0.12%

Held by 10 FIIs

DII

93.45%

Held by 6 DIIs

Promoter

1.84%

How big is Viracta Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Viracta Therapeutics, Inc. has a market capitalization of 0.69 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -43.29 million over the latest four quarters. The company's shareholder's funds are 18.32 million, and total assets are 56.69 million as of Dec 23.

Market Cap: As of Jun 18, Viracta Therapeutics, Inc. has a market capitalization of 0.69 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Viracta Therapeutics reported net sales of 0.00 million and a net profit of -43.29 million.<BR><BR>Balance Sheet Snapshot: As of Dec 23, the company's shareholder's funds amounted to 18.32 million, while total assets were reported at 56.69 million.

Read More

What does Viracta Therapeutics, Inc. do?

22-Jun-2025

Viracta Therapeutics, Inc. is a biopharmaceutical company developing targeted inhibitors for hematologic and solid cancers, classified as a micro-cap with a market cap of $0.69 million and a recent net profit of -$11 million.

Overview:<BR>Viracta Therapeutics, Inc. is a biopharmaceutical company focused on the development of targeted inhibitors for the treatment of hematologic and solid cancers, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -11 Million (Quarterly Results - Sep 2024) <BR>Market-cap: USD 0.69 Million (Micro Cap)<BR><BR>Key Metrics:<BR>Debt Equity: 0.64 <BR>Return on Equity: 643.63% <BR>Price to Book: -0.10<BR><BR>Contact Details:<BR>Address: 395 Oyster Point Blvd Ste 400, SOUTH SAN FRANCISCO CA : 94080-1995 <BR>Tel: 1 650 2663500 <BR>Fax: 1 650 2663501 <BR>Website: http://www.sunesis.com/

Read More

Who are in the management team of Viracta Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Viracta Therapeutics, Inc. includes Non-Executive Independent Chairman Mr. James Young, Directors Dr. Stephen Ketchum and Mr. H. Ward Wolff, and Independent Directors Mr. Steve Carchedi and Mr. Matthew Fust. They guide the company's strategic direction and governance.

As of March 2022, the management team of Viracta Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. James Young, who serves as the Non-Executive Independent Chairman of the Board.<BR>- Dr. Stephen Ketchum, who is a Director.<BR>- Mr. H. Ward Wolff, also a Director.<BR>- Mr. Steve Carchedi, who is an Independent Director.<BR>- Mr. Matthew Fust, another Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and governance.

Read More

Is Viracta Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of February 24, 2021, Viracta Therapeutics, Inc. is considered overvalued with a negative price-to-book value and an EV to EBITDA ratio indicating no market confidence in recovery, while its stock has declined 89.93% year-to-date, significantly underperforming the S&P 500.

As of 24 February 2021, the valuation grade for Viracta Therapeutics, Inc. moved from risky to does not qualify, indicating a significant deterioration in its valuation outlook. The company is currently considered overvalued given its negative price-to-book value of -0.10 and an EV to EBITDA ratio of 0.08, which suggests that the market is not pricing in any potential for recovery or profitability. The return on capital employed (ROCE) is exceptionally high at 429.14%, but this is misleading due to the company's loss-making status.<BR><BR>In comparison to its peers, Viracta's valuation metrics are concerning; for instance, Solid Biosciences, Inc. has a P/E of -2.6812, while Instil Bio, Inc. shows a P/E of -3.7811, both indicating similar struggles within the sector. The company's stock has significantly underperformed against the S&P 500, with a year-to-date decline of 89.93% compared to the index's modest gain of 2.44%. Overall, Viracta Therapeutics, Inc. appears to be overvalued in the current market environment.

Read More

Is Viracta Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of June 9, 2025, Viracta Therapeutics, Inc. shows a mildly bearish trend due to bearish daily moving averages and mixed signals from other indicators, with a year-to-date return of -93.91% compared to the S&P 500's 12.22%.

As of 9 June 2025, the technical trend for Viracta Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are bearish, and the weekly Bollinger Bands are mildly bearish, which adds to the bearish sentiment. The KST shows a mildly bullish stance on the weekly but is bearish on the monthly, and the OBV is mildly bullish on the monthly but shows no trend on the weekly.<BR><BR>In terms of performance, the stock has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -93.91% versus the S&P 500's 12.22%, and a one-year return of -98.24% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven primarily by the bearish daily moving averages and the mixed signals from other indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.64

stock-summary
Return on Equity

643.63%

stock-summary
Price to Book

-0.06

Revenue and Profits:
Net Sales:
(Quarterly Results - Sep 2024)
Net Profit:
-11 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-41.67%
0%
-41.67%
6 Months
-94.55%
0%
-94.55%
1 Year
-98.24%
0%
-98.24%
2 Years
-99.32%
0%
-99.32%
3 Years
-99.78%
0%
-99.78%
4 Years
-99.91%
0%
-99.91%
5 Years
-96.27%
0%
-96.27%

Viracta Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Viracta Therapeutics, Inc. technically bullish or bearish?

As of 9 June 2025, the technical trend for Viracta Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are bearish, and the weekly Bollinger Bands are mildly bearish, which adds to the bearish sentiment. The KST shows a mildly bullish stance on the weekly but is bearish on the monthly, and the OBV is mildly bullish on the monthly but shows no trend on the weekly. In terms of performance, the stock has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -93.91% versus the S&P 500's 12.22%, and a one-year return of -98.24% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven primarily by the bearish daily moving averages and the mixed signals from ...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-48.36%
EBIT to Interest (avg)
-26.78
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.64
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
30.63%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.10
EV to EBIT
0.08
EV to EBITDA
0.08
EV to Capital Employed
0.33
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
429.14%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 7 Schemes (4.6%)

Foreign Institutions

Held by 10 Foreign Institutions (0.12%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2024 is 0.00% vs 0.00% in Sep 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2024 is 15.87% vs 28.81% in Sep 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.40",
          "val2": "-12.30",
          "chgp": "23.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "1.00",
          "chgp": "-30.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.60",
          "val2": "-12.60",
          "chgp": "15.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -3.86% vs 57.14% in Dec 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-50.20",
          "val2": "-50.40",
          "chgp": "0.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.70",
          "val2": "0.60",
          "chgp": "516.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-51.10",
          "val2": "-49.20",
          "chgp": "-3.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'24 - YoYstock-summary
Sep'24
Sep'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-9.40
-12.30
23.58%
Interest
0.70
1.00
-30.00%
Exceptional Items
-0.70
0.00
Consolidate Net Profit
-10.60
-12.60
15.87%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Sep 2024 is 0.00% vs 0.00% in Sep 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2024 is 15.87% vs 28.81% in Sep 2023

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-50.20
-50.40
0.40%
Interest
3.70
0.60
516.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-51.10
-49.20
-3.86%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -3.86% vs 57.14% in Dec 2022

All Annual Resultsstock-summary
stock-summaryCompany CV
About Viracta Therapeutics, Inc. stock-summary
stock-summary
Viracta Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of targeted inhibitors for the treatment of hematologic and solid cancers. The Company’s lead programs are Vecabrutinib, a selective non-covalent inhibitor of Bruton’s Tyrosine Kinase (BTK) inhibitors is in Phase Ib/II clinical trial. The Company is also developing SNS-510, a phosphoinositide dependent protein kinase 1 (PDK1) inhibitor and TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. The Company also offers Vosaroxin, an anticancer quinolone derivative (AQD), which is used for the treatment of acute myeloid leukemia (AML).
Company Coordinates stock-summary
Company Details
395 Oyster Point Blvd Ste 400 , SOUTH SAN FRANCISCO CA : 94080-1995
stock-summary
Tel: 1 650 2663500
stock-summary
http://www.sunesis.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."